GeneDx announced on February 13, 2025, the launch of ultraRapid Whole Genome Sequencing, a new product offering accelerated genomic insights for neonatal and pediatric patients in the NICU and PICU. This service delivers actionable results in as soon as 48 hours, addressing the underutilization of genetic testing in these critical care settings.
The ultraRapid genome testing is designed to provide faster diagnoses, which can shorten NICU stays and lead to significant healthcare savings, estimated at over $15,000 per child. Genetic diseases are a leading cause of infant death, and earlier diagnosis can impact clinical management for over 60% of critically ill infants.
Despite up to 25% of NICU patients likely having a genetic disorder, less than 5% currently undergo genetic testing. GeneDx's ultraRapid genome, available for ordering in March via its portal and Epic Aura integration, aims to bridge this gap by providing critical information to patients, providers, and families when it is most needed.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.